Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.

Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, Graff-Radford J, Jones DT, Ferman TJ, Boeve BF, Kantarci K, Lowe VJ, Vemuri P, Mielke MM, Fields JA, Machulda MM, Schwarz CG, Senjem ML, Gunter JL, Petersen RC.

Brain. 2019 Sep 9. pii: awz268. doi: 10.1093/brain/awz268. [Epub ahead of print]

PMID:
31501889
2.

Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework.

Jack CR Jr, Therneau TM, Weigand SD, Wiste HJ, Knopman DS, Vemuri P, Lowe VJ, Mielke MM, Roberts RO, Machulda MM, Graff-Radford J, Jones DT, Schwarz CG, Gunter JL, Senjem ML, Rocca WA, Petersen RC.

JAMA Neurol. 2019 Jul 15. doi: 10.1001/jamaneurol.2019.1971. [Epub ahead of print]

3.

Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.

Jack CR Jr, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, Lowe VJ, Vemuri P, Machulda MM, Schwarz CG, Gunter JL, Senjem ML, Graff-Radford J, Jones DT, Roberts RO, Rocca WA, Petersen RC.

JAMA. 2019 Jun 18;321(23):2316-2325. doi: 10.1001/jama.2019.7437.

PMID:
31211344
4.

Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults.

Lowe VJ, Bruinsma TJ, Wiste HJ, Min HK, Weigand SD, Fang P, Senjem ML, Therneau TM, Boeve BF, Josephs KA, Pandey MK, Murray ME, Kantarci K, Jones DT, Vemuri P, Graff-Radford J, Schwarz CG, Machulda MM, Mielke MM, Roberts RO, Knopman DS, Petersen RC, Jack CR Jr.

Neurology. 2019 Jul 2;93(1):e29-e39. doi: 10.1212/WNL.0000000000007728. Epub 2019 May 30.

PMID:
31147421
5.

Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa.

Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Knopman DS, Petersen RC, Jack CR Jr, Whitwell JL, Dickson DW.

Alzheimers Dement. 2019 Jun;15(6):799-806. doi: 10.1016/j.jalz.2019.03.003. Epub 2019 May 2.

PMID:
31056344
6.

The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease.

Whitwell JL, Martin P, Graff-Radford J, Machulda MM, Senjem ML, Schwarz CG, Weigand SD, Spychalla AJ, Drubach DA, Jack CR Jr, Lowe VJ, Josephs KA.

Alzheimers Dement. 2019 May;15(5):675-685. doi: 10.1016/j.jalz.2018.12.016. Epub 2019 Mar 8.

PMID:
30853465
7.

The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals.

Wennberg AM, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Machulda MM, Petrucelli L, Mielke MM, Jack CR Jr, Knopman DS, Parisi JE, Petersen RC, Dickson DW, Josephs KA.

Neurobiol Aging. 2019 May;77:26-36. doi: 10.1016/j.neurobiolaging.2019.01.008. Epub 2019 Jan 21.

PMID:
30776649
8.

The influence of β-amyloid on [18F]AV-1451 in semantic variant of primary progressive aphasia.

Whitwell JL, Martin PR, Duffy JR, Clark HM, Machulda MM, Schwarz CG, Weigand SD, Sintini I, Senjem ML, Ertekin-Taner N, Botha H, Utianski RL, Graff-Radford J, Jones DT, Boeve BF, Knopman DS, Petersen RC, Jack CR Jr, Lowe VJ, Josephs KA.

Neurology. 2019 Feb 12;92(7):e710-e722. doi: 10.1212/WNL.0000000000006913. Epub 2019 Jan 11.

PMID:
30635491
9.

Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains.

Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Perkerson RB, Matchett BJ, Jack CR Jr, Knopman DS, Petersen RC, Parisi JE, Petrucelli L, Baker M, Rademakers R, Whitwell JL, Dickson DW.

Acta Neuropathol. 2019 Feb;137(2):227-238. doi: 10.1007/s00401-018-1951-7. Epub 2019 Jan 2.

PMID:
30604226
10.

Predicting Progression to Mild Cognitive Impairment.

Petersen RC, Lundt ES, Therneau TM, Weigand SD, Knopman DS, Mielke MM, Roberts RO, Lowe VJ, Machulda MM, Kremers WK, Geda YE, Jack CR Jr.

Ann Neurol. 2019 Jan;85(1):155-160. doi: 10.1002/ana.25388. Epub 2019 Jan 7.

PMID:
30521086
11.

TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia.

Sahoo A, Bejanin A, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Senjem ML, Machulda MM, Parisi JE, Boeve BF, Knopman DS, Petersen RC, Dickson DW, Whitwell JL, Josephs KA.

J Alzheimers Dis. 2018;64(4):1227-1233. doi: 10.3233/JAD-180169.

12.

Dark Rims: Novel Sequence Enhances Diagnostic Specificity in Multiple Sclerosis.

Tillema JM, Weigand SD, Dayan M, Shu Y, Kantarci OH, Lucchinetti CF, Port JD.

AJNR Am J Neuroradiol. 2018 Jun;39(6):1052-1058. doi: 10.3174/ajnr.A5636. Epub 2018 Apr 26.

13.

Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.

Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD, Machulda MM, Senjem ML, Spychalla AJ, Vemuri P, Jones DT, Drubach DA, Knopman DS, Boeve BF, Ertekin-Taner N, Petersen RC, Lowe VJ, Jack CR Jr, Josephs KA.

Alzheimers Dement. 2018 Aug;14(8):1005-1014. doi: 10.1016/j.jalz.2018.02.020. Epub 2018 Mar 30.

14.

Longitudinal tau PET in ageing and Alzheimer's disease.

Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, Weigand SD, Therneau TM, Knopman DS, Gunter JL, Jones DT, Graff-Radford J, Kantarci K, Roberts RO, Mielke MM, Machulda MM, Petersen RC.

Brain. 2018 May 1;141(5):1517-1528. doi: 10.1093/brain/awy059.

15.

[18 F]AV-1451 tau-PET and primary progressive aphasia.

Josephs KA, Martin PR, Botha H, Schwarz CG, Duffy JR, Clark HM, Machulda MM, Graff-Radford J, Weigand SD, Senjem ML, Utianski RL, Drubach DA, Boeve BF, Jones DT, Knopman DS, Petersen RC, Jack CR Jr, Lowe VJ, Whitwell JL.

Ann Neurol. 2018 Mar;83(3):599-611. doi: 10.1002/ana.25183. Epub 2018 Mar 13.

16.

Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly.

Fatemi F, Kantarci K, Graff-Radford J, Preboske GM, Weigand SD, Przybelski SA, Knopman DS, Machulda MM, Roberts RO, Mielke MM, Petersen RC, Jack CR Jr, Vemuri P.

Neurology. 2018 Feb 6;90(6):e466-e473. doi: 10.1212/WNL.0000000000004913. Epub 2018 Jan 17.

17.

[18 F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease.

Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD, Machulda M, Senjem ML, Schwarz CG, Spychalla AJ, Jones DT, Drubach DA, Knopman DS, Boeve BF, Ertekin-Taner N, Petersen RC, Lowe VJ, Jack CR Jr, Josephs KA.

Ann Neurol. 2018 Feb;83(2):248-257. doi: 10.1002/ana.25142. Epub 2018 Feb 6.

18.

Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.

Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Therneau TM, Boeve BF, Josephs KA, Fang P, Pandey MK, Murray ME, Kantarci K, Jones DT, Vemuri P, Graff-Radford J, Schwarz CG, Machulda MM, Mielke MM, Roberts RO, Knopman DS, Petersen RC, Jack CR Jr.

Brain. 2018 Jan 1;141(1):271-287. doi: 10.1093/brain/awx320.

19.

Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech.

Whitwell JL, Weigand SD, Duffy JR, Clark HM, Strand EA, Machulda MM, Spychalla AJ, Senjem ML, Jack CR Jr, Josephs KA.

Neurology. 2017 Nov 28;89(22):2271-2279. doi: 10.1212/WNL.0000000000004685. Epub 2017 Nov 1.

20.

Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study.

Josephs KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L, Liesinger AM, Senjem ML, Spychalla AJ, Knopman DS, Parisi JE, Petersen RC, Jack CR Jr, Whitwell JL.

Lancet Neurol. 2017 Nov;16(11):917-924. doi: 10.1016/S1474-4422(17)30284-3. Epub 2017 Sep 11.

21.

Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.

Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, Vemuri P, Mielke MM, Roberts RO, Machulda MM, Senjem ML, Gunter JL, Rocca WA, Petersen RC.

Lancet Neurol. 2017 Jun;16(6):435-444. doi: 10.1016/S1474-4422(17)30077-7. Epub 2017 Apr 26.

22.

Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions.

Popescu BF, Frischer JM, Webb SM, Tham M, Adiele RC, Robinson CA, Fitz-Gibbon PD, Weigand SD, Metz I, Nehzati S, George GN, Pickering IJ, Brück W, Hametner S, Lassmann H, Parisi JE, Yong G, Lucchinetti CF.

Acta Neuropathol. 2017 Jul;134(1):45-64. doi: 10.1007/s00401-017-1696-8. Epub 2017 Mar 22.

23.

Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica.

Guo Y, Weigand SD, Popescu BF, Lennon VA, Parisi JE, Pittock SJ, Parks NE, Clardy SL, Howe CL, Lucchinetti CF.

Acta Neuropathol. 2017 Apr;133(4):597-612. doi: 10.1007/s00401-017-1682-1. Epub 2017 Feb 9.

24.

Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART).

Josephs KA, Murray ME, Tosakulwong N, Whitwell JL, Knopman DS, Machulda MM, Weigand SD, Boeve BF, Kantarci K, Petrucelli L, Lowe VJ, Jack CR Jr, Petersen RC, Parisi JE, Dickson DW.

Acta Neuropathol. 2017 May;133(5):705-715. doi: 10.1007/s00401-017-1681-2. Epub 2017 Feb 3.

25.

A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity.

Schwarz CG, Gunter JL, Wiste HJ, Przybelski SA, Weigand SD, Ward CP, Senjem ML, Vemuri P, Murray ME, Dickson DW, Parisi JE, Kantarci K, Weiner MW, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2016 May 30;11:802-812. doi: 10.1016/j.nicl.2016.05.017. eCollection 2016.

26.

Brain tau deposition linked to systemic causes of death in normal elderly.

Josephs KA, Tosakulwong N, Weigand SD, Murray ME, Whitwell JL, Parisi JE, Dickson DW, Petersen RC.

Neurobiol Aging. 2017 Feb;50:163-166. doi: 10.1016/j.neurobiolaging.2016.11.011. Epub 2016 Nov 24.

27.

Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL, Senjem ML, Jones DT, Kantarci K, Machulda MM, Mielke MM, Roberts RO, Vemuri P, Reyes DA, Petersen RC.

Alzheimers Dement. 2017 Mar;13(3):205-216. doi: 10.1016/j.jalz.2016.08.005. Epub 2016 Sep 30.

28.

[18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy.

Whitwell JL, Lowe VJ, Tosakulwong N, Weigand SD, Senjem ML, Schwarz CG, Spychalla AJ, Petersen RC, Jack CR Jr, Josephs KA.

Mov Disord. 2017 Jan;32(1):124-133. doi: 10.1002/mds.26834. Epub 2016 Oct 27.

29.

Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE.

Schwarz CG, Senjem ML, Gunter JL, Tosakulwong N, Weigand SD, Kemp BJ, Spychalla AJ, Vemuri P, Petersen RC, Lowe VJ, Jack CR Jr.

Neuroimage. 2017 Jan 1;144(Pt A):113-127. doi: 10.1016/j.neuroimage.2016.08.056. Epub 2016 Aug 27.

30.

Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study.

Vemuri P, Knopman DS, Jack CR Jr, Lundt ES, Weigand SD, Zuk SM, Thostenson KB, Reid RI, Kantarci K, Slinin Y, Lakshminarayan K, Davey CS, Murray A.

J Alzheimers Dis. 2017;55(3):1069-1082.

31.

Clinical-radiological-pathological spectrum of central nervous system-idiopathic inflammatory demyelinating disease in the elderly.

Tobin WO, Costanzi C, Guo Y, Parisi JE, Weigand SD, Lucchinetti CF.

Mult Scler. 2017 Aug;23(9):1204-1213. doi: 10.1177/1352458516675748. Epub 2016 Oct 19.

32.

In vivo detection of connectivity between cortical and white matter lesions in early MS.

Tillema JM, Weigand SD, Mandrekar J, Shu Y, Lucchinetti CF, Pirko I, Port JD.

Mult Scler. 2017 Jun;23(7):973-981. doi: 10.1177/1352458516671027. Epub 2016 Oct 3.

33.

Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum.

Knopman DS, Jack CR Jr, Lundt ES, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Machulda MM, Roberts RO, Boeve BF, Jones DT, Petersen RC.

Neurobiol Aging. 2016 Oct;46:32-42. doi: 10.1016/j.neurobiolaging.2016.06.003. Epub 2016 Jun 16.

34.

Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia.

Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Machulda MM, Roberts RO, Boeve BF, Jones DT, Petersen RC.

Neurology. 2016 Aug 16;87(7):691-8. doi: 10.1212/WNL.0000000000002979. Epub 2016 Jul 15.

35.

Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech.

Whitwell JL, Weigand SD, Duffy JR, Strand EA, Machulda MM, Senjem ML, Gunter JL, Lowe VJ, Jack CR Jr, Josephs KA.

Neuroimage Clin. 2016 Jan 20;11:90-98. doi: 10.1016/j.nicl.2016.01.014. eCollection 2016.

36.

Updated TDP-43 in Alzheimer's disease staging scheme.

Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, Liesinger AM, Petersen RC, Parisi JE, Dickson DW.

Acta Neuropathol. 2016 Apr;131(4):571-85. doi: 10.1007/s00401-016-1537-1. Epub 2016 Jan 25.

37.

Progressive supranuclear palsy: progression and survival.

Arena JE, Weigand SD, Whitwell JL, Hassan A, Eggers SD, Höglinger GU, Litvan I, Josephs KA.

J Neurol. 2016 Feb;263(2):380-389. doi: 10.1007/s00415-015-7990-2. Epub 2015 Dec 24.

PMID:
26705121
38.

Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study.

Jack CR Jr, Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Mielke MM, Vemuri P, Roberts RO, Machulda MM, Senjem ML, Gunter JL, Rocca WA, Petersen RC.

Lancet Neurol. 2016 Jan;15(1):56-64. doi: 10.1016/S1474-4422(15)00323-3. Epub 2015 Nov 18.

39.

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.

Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, Lowe VJ, Knopman DS, Pankratz VS, Machulda MM, Geda YE, Jack CR Jr.

JAMA Neurol. 2016 Jan;73(1):85-92. doi: 10.1001/jamaneurol.2015.3098. Erratum in: JAMA Neurol. 2016 Apr;73(4):481.

40.

Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment.

Knopman DS, Jack CR Jr, Lundt ES, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Machulda MM, Roberts RO, Boeve BF, Jones DT, Petersen RC.

JAMA Neurol. 2015 Dec;72(12):1475-83. doi: 10.1001/jamaneurol.2015.2323.

41.

Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings.

Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Mielke MM, Vemuri P, Lowe V, Senjem ML, Gunter JL, Reyes D, Machulda MM, Roberts R, Petersen RC.

Brain. 2015 Dec;138(Pt 12):3747-59. doi: 10.1093/brain/awv283. Epub 2015 Sep 30.

42.

Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.

Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, Mandrekar J, Bramow S, Metz I, Brück W, Lassmann H, Lucchinetti CF.

Ann Neurol. 2015 Nov;78(5):710-21. doi: 10.1002/ana.24497. Epub 2015 Aug 24.

43.

TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features.

Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, Petrucelli L, Senjem ML, Ivnik RJ, Parisi JE, Petersen RC, Dickson DW.

Ann Neurol. 2015 Nov;78(5):697-709. doi: 10.1002/ana.24493. Epub 2015 Sep 16.

44.

Sample size calculations for clinical trials targeting tauopathies: a new potential disease target.

Whitwell JL, Duffy JR, Strand EA, Machulda MM, Tosakulwong N, Weigand SD, Senjem ML, Spychalla AJ, Gunter JL, Petersen RC, Jack CR Jr, Josephs KA.

J Neurol. 2015 Sep;262(9):2064-72. doi: 10.1007/s00415-015-7821-5. Epub 2015 Jun 17.

45.

Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease.

Vemuri P, Senjem ML, Gunter JL, Lundt ES, Tosakulwong N, Weigand SD, Borowski BJ, Bernstein MA, Zuk SM, Lowe VJ, Knopman DS, Petersen RC, Fox NC, Thompson PM, Weiner MW, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2015 Jun;113:61-9. doi: 10.1016/j.neuroimage.2015.03.026. Epub 2015 Mar 20.

46.

Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span.

Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Vemuri P, Mielke MM, Lowe V, Senjem ML, Gunter JL, Machulda MM, Gregg BE, Pankratz VS, Rocca WA, Petersen RC.

JAMA Neurol. 2015 May;72(5):511-9. doi: 10.1001/jamaneurol.2014.4821.

47.

Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images.

Whitwell JL, Boeve BF, Weigand SD, Senjem ML, Gunter JL, Baker MC, DeJesus-Hernandez M, Knopman DS, Wszolek ZK, Petersen RC, Rademakers R, Jack CR Jr, Josephs KA.

Eur J Neurol. 2015 May;22(5):745-52. doi: 10.1111/ene.12675. Epub 2015 Feb 12.

48.

Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type.

Whitwell JL, Kantarci K, Weigand SD, Lundt ES, Gunter JL, Duffy JR, Strand EA, Machulda MM, Spychalla AJ, Drubach DA, Petersen RC, Lowe VJ, Jack CR Jr, Josephs KA.

J Alzheimers Dis. 2015;45(4):1109-17. doi: 10.3233/JAD-142628.

49.

Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging.

Mielke MM, Weigand SD, Wiste HJ, Vemuri P, Machulda MM, Knopman DS, Lowe V, Roberts RO, Kantarci K, Rocca WA, Jack CR Jr, Petersen RC.

Alzheimers Dement. 2014 Nov;10(6):779-89. doi: 10.1016/j.jalz.2014.09.001. Epub 2014 Nov 15.

50.

Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.

Jack CR Jr, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, Lowe VJ, Senjem ML, Gunter JL, Preboske GM, Pankratz VS, Vemuri P, Petersen RC.

Lancet Neurol. 2014 Oct;13(10):997-1005. doi: 10.1016/S1474-4422(14)70194-2. Epub 2014 Sep 4.

Supplemental Content

Loading ...
Support Center